|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC17
|
|
gptkbp:CASNumber
|
946414-94-4
|
|
gptkbp:combinationTherapy
|
gptkb:Yervoy
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:nivolumab
|
|
gptkbp:halfLife
|
25 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Opdivo
|
|
gptkbp:indication
|
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:head_and_neck_squamous_cell_carcinoma
gptkb:classical_Hodgkin_lymphoma
colorectal cancer
esophageal cancer
melanoma
hepatocellular carcinoma
renal cell carcinoma
|
|
gptkbp:KEGGID
|
D09952
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
PD-1 inhibitor
|
|
gptkbp:molecularWeight
|
146 kDa
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://packageinserts.bms.com/pi/pi_opdivo.pdf
|
|
gptkbp:PubChem_CID
|
DB09037
CHEMBL3187074
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
pruritus
cough
rash
immune-mediated adverse reactions
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:PD-1
|
|
gptkbp:UNII
|
QDL4442L0U
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Bristol_Myers_Squibb
gptkb:BMS
gptkb:百时美施贵宝
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:bfsLayer
|
6
|